Cambridge Cancer Genomics

United Kingdom
Cambridge, England, United Kingdom, CB2 1LA

Company profile

Cambridge Cancer Genomics company profile

Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated. Using simple blood draws, CCG shortens the time required to know whether treatment is working, buying the clinician more time to alter treatment and reduce unnecessary side effects. The technology can detect relapse earlier than standard of care, predict response to therapy, and decrease ineffective treatment regimens. Over time, CCG will be able to better predict the best therapeutic strategy for cancer patients before they even begin treatment. Cambridge Cancer Genomics was founded on 2016 and is headquartered in Cambridge, England.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2016-01-01, Year

Headquarters

Postal code
CB2 1LA
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
2
Total equity funding
$8.5M
Last funding
Seed / $4.5M / 2018-12-31
Last equity funding
Seed / $4.5M
Investors
11
Founders
4
Articles
15
Exited on
2021-06-23

Founders and investors

Founders

Evaline TsaiHarry CliffordJohn CassidyNirmesh Patel

Investors

FundersClubLiquid 2 VenturesRefactorSoma CapitalY Combinator